This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fainstein, V Articles by McCredie, K B Search for Related Content PubMed PubMed Citation Articles by Fainstein, V Articles by McCredie, K B

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1987 January; 31(1): 11-15

Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients.

V Fainstein, G P Bodey, L Elting, A Maksymiuk, M Keating and K B McCredie

ABSTRACT

Fungal infections in neutropenic cancer patients have increased in frequency and constitute an important cause of morbidity and mortality. Empiric antifungal therapy is often administered to those patients who have failed to respond to antibacterial antibiotics. We conducted a prospective, randomized trial of amphotericin B and ketoconazole for 172 neutropenic cancer patients with presumed or proven fungal infections. Overall, amphotericin B and ketoconazole were equally effective. Amphotericin B may have been more effective than ketoconazole for the treatment of pneumonia. Also, five of eight Candida tropicalis infections treated with amphotericin B responded, whereas all eight infections treated with ketoconazole failed to respond (P = 0.03). Response rates for localized fungal infections were similar with both drugs. Ketoconazole should not be used as empiric antifungal therapy at institutions where there is a high frequency of infections caused by Aspergillus spp. or C. tropicalis because this agent lacks activity in vitro against these species.

---

Antimicrob Agents Chemother. 1987 January; 31(1): 11-15

This article has been cited by other articles:

• Gafter-Gvili, A., Vidal, L., Goldberg, E., Leibovici, L., Paul, M. (2008). Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis. Mayo Clin Proc. 83: 1011-1021 [Abstract] [Full Text]  
• Walsh, T. J., Rubin, M., Hathorn, J., Gress, J., Thaler, M., Skelton, J., McKnight, J., Browne, M., Marshall, D., Cotton, D., Hiemenz, J., Longo, D., Wesley, R., Pizzo, P. A. (1991). Amphotericin B vs High-Dose Ketoconazole for Empirical Antifungal Therapy Among Febrile, Granulocytopenic Cancer Patients: A Prospective, Randomized Study. Arch Intern Med 151: 765-770 [Abstract]  
• Marchbanks, C. R., Rowley, K. A. (1991). Update on Infections in the Immunocompromised Host. Journal of Pharmacy Practice 4: 282-294 [Abstract]  
• Sugar, A. M. (1990). Empiric Treatment of Fungal Infections in the Neutropenic Host: Review of the Literature and Guidelines for Use. Arch Intern Med 150: 2258-2264 [Abstract]